{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Famindr.com%2Fepisodes%2F42-preclinical-testing-part-1-alzheimers-disease-august-2020-s_PcN6O_","width":444,"version":"1.0","type":"rich","title":"42 - Preclinical Testing Part 1: Alzheimer's Disease August 2020","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/9a8ef428-72db-47cb-a5cb-a6a258a13785/d5b6120f-fd25-4e77-afdf-782899f60ea6/slide17.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/07f93f6b-bc58-4b43-91d8-6c391455a49d\" height=\"200\" width=\"100%\" title=\"42 - Preclinical Testing Part 1: Alzheimer&apos;s Disease August 2020\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In Part 1 of the AD preclinical testing papers published in August 2020, Naila gets us started with some treatments that target the cholinergic system and synaptic function, tau phosphorylation and resulting pathology, and amyloid-beta mediated toxicity. Given these are some of the hallmarks of AD pathology, trying to prevent or reverse their effects could lead to promising therapeutic outcomes, which these papers first explore in animal models. Naila will also go over a couple miscellaneous — but equally interesting — papers, so stay tuned till the end! "}